BioNotebook: Aegerion lawsuit, Juno funding, Concert IPO, Salix layoffs
This article was originally published in Scrip
Several biotechnology and specialty pharmaceutical companies announced deals and corporate updates during the week of the 32nd Annual JP Morgan Healthcare Conference in San Francisco, which ended on 16 January, and a lot of news was lost in the hubbub of the yearly kickoff event for the biopharma industry. Companies probably are happy to have some news ignored, such as shareholder litigation and employee layoff notices. But in a closely-watched industry with skyrocketing public company values, relevant information eventually comes to light.
You may also be interested in...
Aegerion and QLT will unite to create a new company dubbed Novelion in a deal that could help both companies solve some long-standing issues.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.